tiprankstipranks
Blurbs

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Vertex Pharmaceuticals (VRTX), Natera (NTRA) and Arrowhead Pharmaceuticals (ARWR)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Vertex Pharmaceuticals (VRTXResearch Report), Natera (NTRAResearch Report) and Arrowhead Pharmaceuticals (ARWRResearch Report).

Vertex Pharmaceuticals (VRTX)

In a report issued on August 5, Brian Skorney from Robert W. Baird maintained a Hold rating on Vertex Pharmaceuticals, with a price target of $250.00. The company’s shares closed last Thursday at $292.16, close to its 52-week high of $301.80.

According to TipRanks.com, Skorney ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -4.9% and a 45.3% success rate. Skorney covers the Healthcare sector, focusing on stocks such as Eiger Biopharmaceuticals, Enanta Pharmaceuticals, and VistaGen Therapeutics.

Vertex Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $292.88, which is a -0.8% downside from current levels. In a report issued on July 22, SVB Securities also maintained a Hold rating on the stock.

See today’s best-performing stocks on TipRanks >>

Natera (NTRA)

Robert W. Baird analyst Catherine Ramsey Schulte reiterated a Buy rating on Natera on August 4 and set a price target of $72.00. The company’s shares closed last Thursday at $53.59.

According to TipRanks.com, Schulte is a 5-star analyst with an average return of 17.9% and a 59.1% success rate. Schulte covers the Healthcare sector, focusing on stocks such as Maravai Lifesciences Holdings, Castle Biosciences, and Twist Bioscience.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Natera with a $79.40 average price target, which is a 43.6% upside from current levels. In a report issued on August 5, J.P. Morgan also maintained a Buy rating on the stock with a $100.00 price target.

Arrowhead Pharmaceuticals (ARWR)

Robert W. Baird analyst Joel Beatty maintained a Buy rating on Arrowhead Pharmaceuticals on August 4 and set a price target of $60.00. The company’s shares closed last Thursday at $45.63.

According to TipRanks.com, Beatty is a 4-star analyst with an average return of 6.2% and a 51.9% success rate. Beatty covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, BioMarin Pharmaceutical, and Syndax Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Arrowhead Pharmaceuticals with a $70.17 average price target, which is a 49.4% upside from current levels. In a report issued on August 8, Goldman Sachs also maintained a Buy rating on the stock with a $65.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on VRTX:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles